Literature DB >> 2311475

Effects of prostaglandins and indomethacin on cerebral blood flow and cerebral oxygen consumption of conscious newborn piglets.

S Chemtob1, N Laudignon, K Beharry, J Rex, D Varma, L Wolfe, J V Aranda.   

Abstract

The effects of the prostaglandins (PG) PGE1, PGE2, PGF2 alpha and PGI2, and of indomethacin on cerebral blood flow (CBF) and cerebral metabolic rate for O2 (CMRO2) were studied in 60 1- to 3-day-old conscious piglets. Effects of PGs in indomethacin-treated animals were also measured. CBF was measured by radiolabelled microspheres prior to and 45 s after intracarotid bolus injections of 0.1-10 micrograms/kg PGE1 and 0.01-1 micrograms/kg PGE2, PGF2 alpha and PGI2. PGE1 decreased CBF by 30% at the dose of 0.1 micrograms/kg and increased it by 39.5% (n = 6) at the higher dose of 10 micrograms/kg. PGE2 (n = 6) increased CBF at all doses administered. PGF2 alpha (0.01 micrograms/kg, n = 8), which is a potent cerebral vasoconstrictor in adults, and PGI2 (0.1 micrograms/kg, n = 6) significantly increased CBF in newborn piglets (p less than 0.05). CMRO2 correlated with CBF in all groups of animals, except for those injected with PGI2. Indomethacin (3 mg/kg i.v.) decreased CBF by 39% (p less than 0.01, n = 6). This effect was partially reversed by PGI2, but not by PGE1 and PGF2 alpha. Sagittal venous blood and arterial-sagittal venous blood differences in concentrations of PGF2 alpha, but not of PGE and 6-keto-PGF1 alpha, correlated weakly but positively (r = 0.4, p less than 0.05) with CBF in indomethacin-treated piglets. These data indicate that PGs exert significant effects on cerebral circulation in the newborn. Primary PGs are principally cerebral vasodilators and are devoid of vasoconstrictive effects in the newborn, except for PGE1 which produces vasoconstriction at low dose (0.1 micrograms/kg). Thus, we speculate that a relative deficiency in cerebral vasoconstrictor effect of PGs may contribute to the reduced upper limit of the CBF autoregulatory range of the newborn.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2311475

Source DB:  PubMed          Journal:  Dev Pharmacol Ther        ISSN: 0379-8305


  10 in total

Review 1.  A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.

Authors:  Ronald L Thomas; Graham C Parker; Bart Van Overmeire; Jacob V Aranda
Journal:  Eur J Pediatr       Date:  2004-12-10       Impact factor: 3.183

2.  Treatment of patent ductus arteriosus with ibuprofen.

Authors:  B Van Overmeire; I Follens; S Hartmann; W L Creten; K J Van Acker
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

3.  Clinical considerations for the pharmacologic management of patent ductus arteriosus with cyclooxygenase inhibitors in premature infants.

Authors:  Karen E Corff; Kris C Sekar
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

4.  Premature babies and pharmacology.

Authors:  J Hamilton
Journal:  CMAJ       Date:  1995-12-15       Impact factor: 8.262

Review 5.  Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?

Authors:  Ronald I Clyman; James Couto; Gail M Murphy
Journal:  Semin Perinatol       Date:  2012-04       Impact factor: 3.300

6.  Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs.

Authors:  D Y Li; D R Varma; S Chemtob
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Effect of oral ibuprofen on patent ductus arteriosus in premature newborns.

Authors:  Sabry Ghanem; Mansour Mostafa; Mohamed Shafee
Journal:  J Saudi Heart Assoc       Date:  2010-03-10

8.  Regional Differences in the Neuronal Expression of Cyclooxygenase-2 (COX-2) in the Newborn Pig Brain.

Authors:  Orsolya Oláh; István Németh; Valéria Tóth-Szűki; Ferenc Bari; Ferenc Domoki
Journal:  Acta Histochem Cytochem       Date:  2012-05-15       Impact factor: 1.938

Review 9.  Patent ductus arteriosus in preterm infants: do we have the right answers?

Authors:  Hesham Abdel-Hady; Nehad Nasef; Abd Elazeez Shabaan; Islam Nour
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

10.  Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).

Authors:  Tim Hundscheid; Wes Onland; Bart van Overmeire; Peter Dijk; Anton H L C van Kaam; Koen P Dijkman; Elisabeth M W Kooi; Eduardo Villamor; André A Kroon; Remco Visser; Daniel C Vijlbrief; Susanne M de Tollenaer; Filip Cools; David van Laere; Anne-Britt Johansson; Catheline Hocq; Alexandra Zecic; Eddy Adang; Rogier Donders; Willem de Vries; Arno F J van Heijst; Willem P de Boode
Journal:  BMC Pediatr       Date:  2018-08-04       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.